Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV

• Published in: Science (American Association for the Advancement of Science) 2017-10, Vol.358 (6360), p.218-223
• Main Authors: Wender, Paul A., Hardman, Clayton T., Ho, Stephen, Jeffreys, Matthew S., Maclaren, Jana K., Quiroz, Ryan V., Ryckbosch, Steven M., Shimizu, Akira J., Sloane, Jack L., Stevens, Matthew C.
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adjuvants, Immunologic - chemical synthesis; Adjuvants, Immunologic - chemistry; Adjuvants, Immunologic - pharmacology; Adjuvants, Immunologic - therapeutic use; AIDS; Alzheimer's disease; Analogs; Anti-HIV Agents - chemical synthesis; Anti-HIV Agents - chemistry; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Bryostatins - chemical synthesis; Bryostatins - chemistry; Bryostatins - pharmacology; Bryostatins - therapeutic use; Cancer; Cancer immunotherapy; Chemical synthesis; Chemistry; Disease control; Disease Eradication; HIV; HIV Infections - drug therapy; HIV-1 - drug effects; Human immunodeficiency virus; Humans; Immunotherapy; Intermediates; Medical treatment; Neurodegenerative diseases; Virus Latency - drug effects
• ISSN: 0036-8075; 1095-9203
• DOI: 10.1126/science.aan7969

Bryostatin 1 is an exceedingly scarce marine-derived natural product that is in clinical development directed at HIV/AIDS eradication, cancer immunotherapy, and the treatment of Alzheimer’s disease. Despite this unique portfolio of indications, its availability has been limited and variable, thus impeding research and clinical studies. Here, we report a total synthesis of bryostatin 1 that proceeds in 29 total steps (19 in the longest linear sequence, >80% average yield per step), collectively produces grams of material, and can be scaled to meet clinical needs (∼20 grams per year). This practical solution to the bryostatin supply problem also opens broad, facile, and efficient access to derivatives and potentially superior analogs.